Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice.
OBJECTIVE
Despite recent advances in treatment options, pancreatic cancer remains the most deadly major cancer. Targeting metabolism represents an emerging anti-cancer strategy.


RESULTS
Metagenomic 16S analysis was employed to explore the effect of Dichloroacetate (DCA) on the composition of the fecal microbiota and metabolomic profile was assessed on in vivo pancreatic cancer mouse xenograft model. Pancreatic cancer xenograft mice displayed a shift of microbiota' profile as compared to control mice without DCA treatment and a significant decrease of the purine bases inosine xanthine together with their metabolically-related compound hypoxanthine were observed in the DCA treated group as compared to the control group. Two aminoacids methionine and aspartic acid resulted decreased and increased respectively. DCA affects tumor environment and studies are needed in order to understand whether DCA supplementation could be supportive as synergistic approach to enhance the efficacy of existing cancer treatments in pancreatic cancer patients.
['Adamberg|Kaarel|K|', 'Vilu|Raivo|R|', 'Pazienza|Valerio|V|http://orcid.org/0000-0002-3492-1153']
D000818:Animals D045744:Cell Line, Tumor D003999:Dichloroacetic Acid D006801:Humans D051379:Mice D064307:Microbiota D010190:Pancreatic Neoplasms D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase D023041:Xenograft Model Antitumor Assays
Microbiota Metabolomic Pancreatic cancer